Hyderabad (Telangana) [India], December 28: Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug. Optimus Pharma successfully completed the Phase 3 Clinical Trial on 1218 subjects across 29 geographical study sites all over India. “We want to cover maximum demographic diversity into our trial in order to obtain data across the different geographical regions of the country and conclusive evidence that Molnupiravir is able to bring about viral load reduction over 5 days of treatment duration,” said Chairman and Managing Director of Optimus Pharma, Dr D Srinivasa Reddy. Optimus Pharma has developed the API in the house at its R&D centre in Hyderabad. Optimus Pharma has revealed highly promising results of the drug in its ability to reduce viral load and bring out significant symptomatic improvement in patients’ health.
It is to be noted that in the Clinical Trial, Molnupiravir was administered to the subjects along with Standard of Care (SoC) medication as per the approved protocol by CDSCO. The trial was successful in establishing a clinical significant results of ‘Molnupiravir + SoC’ over ‘SoC’ arm.
- Rate of hospitalization was less in Molnupiravir+SoC when compared to SoC group.
- Greater clinical improvement observed in Molnupiravir + SoC arm compared to SOC alone by Day 5 and Day 10.
- Proportion of subjects with RT-PCR negativity at Day 5 and Day 10 was statistically significant in Molnupiravir + SoC arm.
- Higher viral load reduction was observed in Molnupiravir+ SoC arm
- No serious safety concerns observed with Molnupiravir in overall study duration, no mortality was observed in the trial across both the arms
Molnupiravir is administered as an 800 mg dose by orally consuming four capsules of 200mg twice a day. Upon oral administration, Molnupiravir, being a prodrug, is metabolized into its active form and converted into its triphosphate (TP) form. The TP form of Molnupiravir is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription, thereby significantly reducing viral replication.
Optimus Pharma is ready with a commercial quantity of the drug to cater to the unmet medical need of the nation. It is with heartfelt gratitude that we thank the Subject Expert Committee of the CDSCO and the DCGI for their valuable recommendations and guidance for the Clinical Trial, thereby making this project a huge success, said Dr D. Srinivas Reddy (MD Optimus) in his statement to the press. Optimus Pharma is committed to consistently integrating quality, affordability and reliability into their products and ensuring timely access to life-saving medication to whomsoever is in need.
722904 192101hi there, your web site is discount. Me thank you for do the job 622043
Gｒeat g᧐ods from you, man. I’νе understand yoir stuff previous to and yyou are juѕt extremely great.
Ӏ aｃtually likle wһat yⲟu’vе acquired hｅгe,
cеrtainly ⅼike whɑt you aree sɑying and the way іn whіch
you say it. You mаke it enjoyable and yоu stіll care for to keep it sensіble.
I cаnt wait to гead much mօre fгom ｙߋu.
Τhis is really a great website.
Аlso visit mу pɑge – jasa instagram reach
I thyink this is one of the mօst imⲣortant іnformation for me.
And i’m glad reading үour article. But sһould remark ᧐n feew basic issues, Ƭhe
website style іs perfect, tһe artricles iss іn reality ɡreat : Ɗ.
Excellent process, cheers
Μy web blog; jasa backlink premium
933798 874239Discovered your weblog and decided to have a study on it, not what I generally do, but this blog is fantastic. Awesome to see a internet site thats not spammed, and in fact makes some sense. Anyway, excellent write up. 871586
392214 558716I will right away grab your rss feed to remain up to date on any succeeding articles you might write 484579
Justt wish to say youг article is ɑs astounding. Τhe clearness for ʏօur post iѕ
simply nice and thɑt i can suppose yoᥙ’re knowledgeale
οn thіs subject. Ϝine ԝith yоur permission lett
mе to seize your feed to ҝeep ᥙp to dаte with
approaching post. Thаnks 1,000,000 and please carry on thｅ enjoyable ѡork.
Feeel free tօ visit my web site; seguire questa roba online